Clinical Trial Update: Open-label Study With Bosentan in Interstitial Lung Disease [Phase 2, Phase 3]

View source ↗

Summary

Open-label Phase 2/3 study of bosentan in interstitial lung disease and systemic sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Systemic Sclerosis

Drugs mentioned

• TRACLEER (bosentan)

Snippet

Sponsor: Actelion | Conditions: Interstitial Lung Disease, Scleroderma | Phase 2, Phase 3 | Status: COMPLETED